Search results

The standard care of hospital or emergency department patients experiencing an acute ischemic stroke includes intravenously administered tissue plasminogen activator (tPA). Mobile stroke units (MSUs) are ambulances equipped with staff and a computed tomographic scanner that can allow for tPA to be administered more quickly. This comparative effectiveness trial examined clinical outcomes in stroke patients who received either an earlier diagnosis and treatment using an MSU or standard triage and transport by Emergency Medical Services (EMS). The sample included multicenter cohorts with randomized deployment weeks and blinded assessment of both trial entry and clinical outcomes.

The NEISS-AIP is designed to provide national incidence estimates of all types and external causes of nonfatal injuries and poisonings treated in U.S. hospital EDs. Data on injury-related visits are obtained from a national sample of U.S. NEISS hospitals, which were selected as a stratified probability sample of hospitals in the United States and its territories with a minimum of six beds and a 24- hour ED. The sample includes separate strata for very large, large, medium, and small hospitals, defined by the number of annual ED visits per hospital, and children's hospitals. The scope of reporting goes beyond routine reporting of injuries associated with consumer- related products in CPSC's jurisdiction to include all injuries and poisonings. The data can be used to (1) measure the magnitude and distribution of nonfatal injuries in the United States; (2) monitor unintentional and violence-related nonfatal injuries over time; (3) identify emerging injury problems; (4) identify specific cases for follow-up investigations of particular injury-related problems; and (5) set national priorities. A fundamental principle of this expansion effort is that preliminary surveillance data will be made available in a timely manner to a number of different federal agencies with unique and overlapping public health responsibilities and concerns. The final edited data will be released annually as public use data files for use by other public health professionals and researchers.

These public use data files provide NEISS-AIP data on nonfatal injuries collected from January through December each year.

NEISS-AIP is providing data on approximately over 700,000 cases annually. Data obtained on each case include age, race/ethnicity, sex, principal diagnosis, primary body part affected, consumer products involved, disposition at ED discharge (i.e., hospitalized, transferred, treated and released, observation, died), locale where the injury occurred, work-relatedness, and a narrative description of the injury circumstances. Also, major categories of external cause/mechanism of injury (e.g., motor vehicle, falls, cut/pierce, poisoning, fire/burn) and of intent of injury (e.g., unintentional, assault, intentional self-harm, legal intervention) are being coded for each case in a manner consistent with the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) coding rules and guidelines.

NEISS has been managed and operated by the U.S. Consumer Product Safety Commission since 1972 and is used by the Commission for identifying and monitoring consumer product-related injuries and for assessing risk to all U.S. residents. These product- related injury data are used for educating consumers about hazardous products and for identifying injury-related cases used in detailed studies of specific products and associated hazard patterns. These studies set the stage for developing both voluntary and mandatory safety standards.

Since the early 1980s, CPSC has assisted other federal agencies by using NEISS to collect injury- related data of special interest to them. In 1992, an interagency agreement was established between NCIPC and CPSC to (1) collect NEISS data on nonfatal firearm- related injuries for the CDC Firearm Injury Surveillance Study; (2) publish NEISS data on a variety of injury-related topics, such as in- line skating, firearms, BB and pellet guns, bicycles, boat propellers, personal water craft, and playground injuries; and (3) to address common concerns. CPSC also uses NEISS to collect data on work-related injuries for the National Institute of Occupational Safety and Health (NIOSH), CDC.

In 1997, the interagency agreement was modified to conduct the three-month NEISS All Injury Pilot Study at 21 NEISS hospitals (see Quinlan KP, Thompson MP, Annest JL, et al. Expanding the National Electronic Injury Surveillance System to Monitor All Nonfatal Injuries Treated in US Hospital Emergency Departments. Annals Emerg. Med. 1999;34:637-643.) This study demonstrated the feasibility of expanding NEISS to collect data on all injuries. National estimates based on this study indicated product-related injuries that fall into CPSC's jurisdiction accounted for approximately 50% of injuries treated in U.S. hospital EDs. The study also indicated that NEISS is a cost-effective system for capturing data on all injuries treated in U.S. hospital EDs. The NEISS-AIP provides an excellent data source for monitoring national estimates of nonfatal injuries over time. Analysis and dissemination of these surveillance data through the ICPSR, the internet, and publications will help support NCIPC's mission of reducing all types and causes of injuries in the United States, as well as assist other federal agencies with responsibilities for injury prevention and control.

In July 2000, NCIPC, in collaboration with CPSC, expanded NEISS to collect data on all types and causes of injuries treated in a representative sample of hospitals. This system is called the "NEISS All-Injury Program (NEISS-AIP)". These data provide the basis for national estimates of all types of nonfatal injuries treated in hospital emergency departments in the United States.

Beginning in 2019, CPSC initiated a redesign of the NEISS sample to update the sampling frame. The redesign includes adding and replacing hospitals. The redesign includes a resample based on more recent hospital information from the American Hospital Association, including the list of hospitals by hospital type. The prior sample was drawn in 1997. In 2023, the NEISS-AIP sample increased to 78. The NEISS-AIP sample goal is 100 hospitals; hospital recruitment and onboarding are ongoing. CDC and CPSC are continuing to release injury data while the onboarding is underway. Users are cautioned against using estimates with wide confidence intervals to make conclusions about point estimates. At this time, CDC does not recommend using these data for national firearm injury prevalence estimates. Firearm injuries have distinct geographic patterns and estimates can be imprecise or change over time when based on a small number of facilities.

After pediatric injury, posttraumatic stress and other emotional outcomes in children and their parents often go unrecognized and untreated. This is due in part to the challenges in identifying at-risk children and their parents in the emergency care setting. The aims of this study were to assess the extent to which nurses were able to implement a brief screener for posttraumatic stress symptoms risk within the course of normal care of injured patients, and to assess posttraumatic stress and depression symptoms in injured children (aged 8-17 years) and their parents after emergency department care, and the relationship of these symptoms to parent-reported overall recovery.

The NEISS-AIP is designed to provide national incidence estimates of all types and external causes of nonfatal injuries and poisonings treated in U.S. hospital EDs. Data on injury-related visits are obtained from a national sample of U.S. NEISS hospitals, which were selected as a stratified probability sample of hospitals in the United States and its territories with a minimum of six beds and a 24- hour ED. The sample includes separate strata for very large, large, medium, and small hospitals, defined by the number of annual ED visits per hospital, and children's hospitals. The scope of reporting goes beyond routine reporting of injuries associated with consumer- related products in CPSC's jurisdiction to include all injuries and poisonings. The data can be used to (1) measure the magnitude and distribution of nonfatal injuries in the United States; (2) monitor unintentional and violence-related nonfatal injuries over time; (3) identify emerging injury problems; (4) identify specific cases for follow-up investigations of particular injury-related problems; and (5) set national priorities. A fundamental principle of this expansion effort is that preliminary surveillance data will be made available in a timely manner to a number of different federal agencies with unique and overlapping public health responsibilities and concerns. The final edited data will be released annually as public use data files for use by other public health professionals and researchers.

These public use data files provide NEISS-AIP data on nonfatal injuries collected from January through December each year.

NEISS-AIP is providing data on approximately over 500,000 cases annually. Data obtained on each case include age, race/ethnicity, sex, principal diagnosis, primary body part affected, consumer products involved, disposition at ED discharge (i.e., hospitalized, transferred, treated and released, observation, died), locale where the injury occurred, work-relatedness, and a narrative description of the injury circumstances. Also, major categories of external cause/mechanism of injury (e.g., motor vehicle, falls, cut/pierce, poisoning, fire/burn) and of intent of injury (e.g., unintentional, assault, intentional self-harm, legal intervention) are being coded for each case in a manner consistent with the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) coding rules and guidelines.

NEISS has been managed and operated by the U.S. Consumer Product Safety Commission since 1972 and is used by the Commission for identifying and monitoring consumer product-related injuries and for assessing risk to all U.S. residents. These product- related injury data are used for educating consumers about hazardous products and for identifying injury-related cases used in detailed studies of specific products and associated hazard patterns. These studies set the stage for developing both voluntary and mandatory safety standards.

Since the early 1980s, CPSC has assisted other federal agencies by using NEISS to collect injury- related data of special interest to them. In 1992, an interagency agreement was established between NCIPC and CPSC to (1) collect NEISS data on nonfatal firearm- related injuries for the CDC Firearm Injury Surveillance Study; (2) publish NEISS data on a variety of injury-related topics, such as in- line skating, firearms, BB and pellet guns, bicycles, boat propellers, personal water craft, and playground injuries; and (3) to address common concerns. CPSC also uses NEISS to collect data on work-related injuries for the National Institute of Occupational Safety and Health (NIOSH), CDC.

In 1997, the interagency agreement was modified to conduct the three-month NEISS All Injury Pilot Study at 21 NEISS hospitals (see Quinlan KP, Thompson MP, Annest JL, et al. Expanding the National Electronic Injury Surveillance System to Monitor All Nonfatal Injuries Treated in US Hospital Emergency Departments. Annals Emerg. Med. 1999;34:637-643.) This study demonstrated the feasibility of expanding NEISS to collect data on all injuries. National estimates based on this study indicated product-related injuries that fall into CPSC's jurisdiction accounted for approximately 50% of injuries treated in U.S. hospital EDs. The study also indicated that NEISS is a cost-effective system for capturing data on all injuries treated in U.S. hospital EDs. The NEISS-AIP provides an excellent data source for monitoring national estimates of nonfatal injuries over time. Analysis and dissemination of these surveillance data through the ICPSR, the internet, and publications will help support NCIPC's mission of reducing all types and causes of injuries in the United States, as well as assist other federal agencies with responsibilities for injury prevention and control.

In July 2000, NCIPC, in collaboration with CPSC, expanded NEISS to collect data on all types and causes of injuries treated in a representative sample of hospitals. This system is called the "NEISS All-Injury Program (NEISS-AIP)". These data provide the basis for national estimates of all types of nonfatal injuries treated in hospital emergency departments in the United States.

Beginning in 2019, CPSC initiated a redesign of the NEISS sample to update the sampling frame. The redesign includes adding and replacing hospitals. The redesign includes a resample based on more recent hospital information from the American Hospital Association, including the list of hospitals by hospital type. The prior sample was drawn in 1997. In 2022, the NEISS-AIP sample increased to 78 from 56 in 2021. The NEISS-AIP sample goal is 100 hospitals; hospital recruitment and onboarding are ongoing. CDC and CPSC are continuing to release injury data while the onboarding is underway. Users are cautioned against using estimates with wide confidence intervals to make conclusions about point estimates. At this time, CDC does not recommend using these data for national firearm injury prevalence estimates. Firearm injuries have distinct geographic patterns and estimates can be imprecise or change over time when based on a small number of facilities.

Children and youth, aged 8 - 18 years, were invited to participate in this study after being treated in an emergency department (ED) for an injury resulting from interpersonal community violence. Each invited youth also had to have been living within specified postal codes (urban areas surrounding the hospital). Following the youth's baseline assessment (T1), participants completed between 0 and 4 follow-up assessments. The timing of each follow-up assessment was scheduled according to the relative time since the index (violent injury) event occurred. The average follow-up assessment was conducted at 27 days (T3), 75 days (T5), 199 days (T7), and 467 days (T10).

Beginning in July 2000, the National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention (CDC) in collaboration with the United States Consumer Product Safety Commission (CPSC) expanded the National Electronic Injury Surveillance System (NEISS) to collect data on all types and causes of injuries treated in a representative sample of United States hospitals with emergency departments (EDs). This system is called the NEISS-All Injury Program (NEISS-AIP).

The NEISS-AIP is designed to provide national incidence estimates of all types and external causes of nonfatal injuries and poisonings treated in U.S. hospital EDs. Data on injury-related visits are being obtained from a national sample of U.S. NEISS hospitals, which were selected as a stratified probability sample of hospitals in the United States and its territories with a minimum of six beds and a 24-hour ED. The sample includes separate strata for very large, large, medium, and small hospitals, defined by the number of annual ED visits per hospital, and children's hospitals. The scope of reporting goes beyond routine reporting of injuries associated with consumer-related products in CPSC's jurisdiction to include all injuries and poisonings. The data can be used to (1) measure the magnitude and distribution of nonfatal injuries in the United States; (2) monitor unintentional and violence-related nonfatal injuries over time; (3) identify emerging injury problems; (4) identify specific cases for follow-up investigations of particular injury-related problems; and (5) set national priorities. A fundamental principle of this expansion effort is that preliminary surveillance data will be made available in a timely manner to a number of different federal agencies with unique and overlapping public health responsibilities and concerns. Also, annually, the final edited data will be released as public use data files for use by other public health professionals and researchers. NEISS-AIP data on nonfatal injuries were collected from January through December each year except the year 2000 when data were collected from July through December (ICPSR 3582).

NEISS AIP is providing data on approximately over 500,000 cases annually. Data obtained on each case include age, race/ethnicity, gender, principal diagnosis, primary body part affected, consumer products involved, disposition at ED discharge (i.e., hospitalized, transferred, treated and released, observation, died), locale where the injury occurred, work-relatedness, and a narrative description of the injury circumstances. Also, major categories of external cause of injury (e.g., motor vehicle, falls, cut/pierce, poisoning, fire/burn) and of intent of injury (e.g., unintentional, assault, intentional self-harm, legal intervention) are being coded for each case in a manner consistent with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding rules and guidelines. NEISS has been managed and operated by the United States Consumer Product Safety Commission since 1972 and is used by the Commission for identifying and monitoring consumer product-related injuries and for assessing risk to all United States residents. These product-related injury data are used for educating consumers about hazardous products and for identifying injury-related cases used in detailed studies of specific products and associated hazard patterns. These studies set the stage for developing both voluntary and mandatory safety standards.

Since the early 1980s, CPSC has assisted other federal agencies by using NEISS to collect injury- related data of special interest to them. In 1990, an interagency agreement was established between NCIPC and CPSC to (1) collect NEISS data on nonfatal firearm-related injuries for the CDC Firearm Injury Surveillance Study; (2) publish NEISS data on a variety of injury-related topics, such as in-line skating, firearms, BB and pellet guns, bicycles, boat propellers, personal water craft, and playground injuries; and (3) to address common concerns. CPSC also uses NEISS to collect data on work-related injuries for the National Institute of Occupational Safety and Health (NIOSH), CDC. In 1997, the interagency agreement was modified to conduct the three-month NEISS All Injury Pilot Study at 21 NEISS hospitals (see Quinlan KP, Thompson MP, Annest JL, et al. Expanding the National Electronic Injury Surveillance System to Monitor All Nonfatal Injuries Treated in US Hospital Emergency Departments. Annals Emerg. Med. 1999;34:637-643.) This study demonstrated the feasibility of expanding NEISS to collect data on all injuries. National estimates based on this study indicated product-related injuries that fall into CPSC's jurisdiction accounted for approximately 50 percent of injuries treated in U.S. hospital EDs. The study also indicated that NEISS is a cost-effective system for capturing data on all injuries treated in U.S. hospital EDs. The NEISS-AIP provides an excellent data source for monitoring national estimates of nonfatal injuries over time. Analysis and dissemination of these surveillance data through the ICPSR, and Internet publications will help support NCIPC's mission of reducing all types and causes of injuries in the United States, as well as assist other federal agencies with responsibilities for injury prevention and control.

Three dashboards describe nonfatal drug overdoses within the United States:

1. DOSE Dashboard: Nonfatal Overdose Syndromic Surveillance Data
2. DOSE Dashboard: Nonfatal Overdose Emergency Department and Inpatient Hospitalization Discharge Data
3. The Fentalog Study: A Subset of Nonfatal Suspected Opioid Overdoses with Toxicology Testing

Beginning in July 2000, the National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention (CDC) in collaboration with the United States Consumer Product Safety Commission (CPSC) expanded the National Electronic Injury Surveillance System (NEISS) to collect data on all types and causes of injuries treated in a representative sample of United States hospitals with emergency departments (EDs). This system is called the NEISS-All Injury Program (NEISS-AIP).

The NEISS-AIP is designed to provide national incidence estimates of all types and external causes of nonfatal injuries and poisonings treated in U.S. hospital EDs. Data on injury-related visits are being obtained from a national sample of U.S. NEISS hospitals, which were selected as a stratified probability sample of hospitals in the United States and its territories with a minimum of six beds and a 24-hour ED. The sample includes separate strata for very large, large, medium, and small hospitals, defined by the number of annual ED visits per hospital, and children's hospitals. The scope of reporting goes beyond routine reporting of injuries associated with consumer-related products in CPSC's jurisdiction to include all injuries and poisonings. The data can be used to (1) measure the magnitude and distribution of nonfatal injuries in the United States; (2) monitor unintentional and violence-related nonfatal injuries over time; (3) identify emerging injury problems; (4) identify specific cases for follow-up investigations of particular injury-related problems; and (5) set national priorities. A fundamental principle of this expansion effort is that preliminary surveillance data will be made available in a timely manner to a number of different federal agencies with unique and overlapping public health responsibilities and concerns. Also, annually, the final edited data will be released as public use data files for use by other public health professionals and researchers. NEISS-AIP data on nonfatal injuries were collected from January through December each year except the year 2000 when data were collected from July through December (ICPSR 3582).

NEISS AIP is providing data on approximately over 500,000 cases annually. Data obtained on each case include age, race/ethnicity, gender, principal diagnosis, primary body part affected, consumer products involved, disposition at ED discharge (i.e., hospitalized, transferred, treated and released, observation, died), locale where the injury occurred, work-relatedness, and a narrative description of the injury circumstances. Also, major categories of external cause of injury (e.g., motor vehicle, falls, cut/pierce, poisoning, fire/burn) and of intent of injury (e.g., unintentional, assault, intentional self-harm, legal intervention) are being coded for each case in a manner consistent with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding rules and guidelines. NEISS has been managed and operated by the United States Consumer Product Safety Commission since 1972 and is used by the Commission for identifying and monitoring consumer product-related injuries and for assessing risk to all United States residents. These product-related injury data are used for educating consumers about hazardous products and for identifying injury-related cases used in detailed studies of specific products and associated hazard patterns. These studies set the stage for developing both voluntary and mandatory safety standards.

Since the early 1980s, CPSC has assisted other federal agencies by using NEISS to collect injury- related data of special interest to them. In 1990, an interagency agreement was established between NCIPC and CPSC to (1) collect NEISS data on nonfatal firearm-related injuries for the CDC Firearm Injury Surveillance Study; (2) publish NEISS data on a variety of injury-related topics, such as in-line skating, firearms, BB and pellet guns, bicycles, boat propellers, personal water craft, and playground injuries; and (3) to address common concerns. CPSC also uses NEISS to collect data on work-related injuries for the National Institute of Occupational Safety and Health (NIOSH), CDC. In 1997, the interagency agreement was modified to conduct the three-month NEISS All Injury Pilot Study at 21 NEISS hospitals (see Quinlan KP, Thompson MP, Annest JL, et al. Expanding the National Electronic Injury Surveillance System to Monitor All Nonfatal Injuries Treated in US Hospital Emergency Departments. Annals Emerg. Med. 1999;34:637-643.) This study demonstrated the feasibility of expanding NEISS to collect data on all injuries. National estimates based on this study indicated product-related injuries that fall into CPSC's jurisdiction accounted for approximately 50 percent of injuries treated in U.S. hospital EDs. The study also indicated that NEISS is a cost-effective system for capturing data on all injuries treated in U.S. hospital EDs. The NEISS-AIP provides an excellent data source for monitoring national estimates of nonfatal injuries over time. Analysis and dissemination of these surveillance data through the ICPSR, and Internet publications will help support NCIPC's mission of reducing all types and causes of injuries in the United States, as well as assist other federal agencies with responsibilities for injury prevention and control.

Antibiotics are considered a feasible treatment for appendicitis, yet appendectomy remains the treatment standard in the United States. Previous randomized trials comparing these treatments excluded important subgroups and recruited small sample sizes but questions remain about the applicability of these previous findings. This study conducted the Comparison of Outcomes of antibiotic Drugs and Appendectomy (CODA) randomized clinical trial to compare antibiotics with appendectomy among adults with appendicitis, including those with appendicolith. Those recruited comprised a diverse population, compared an overall measure of health status as the primary outcome, and included several secondary clinical and patient-reported outcomes, complications, and measures of healthcare utilization.

Beginning in July 2000, the National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention (CDC) in collaboration with the United States Consumer Product Safety Commission (CPSC) expanded the National Electronic Injury Surveillance System (NEISS) to collect data on all types and causes of injuries treated in a representative sample of United States hospitals with emergency departments (EDs). This system is called the NEISS-All Injury Program (NEISS-AIP).

The NEISS-AIP is designed to provide national incidence estimates of all types and external causes of nonfatal injuries and poisonings treated in U.S. hospital EDs. Data on injury-related visits are being obtained from a national sample of U.S. NEISS hospitals, which were selected as a stratified probability sample of hospitals in the United States and its territories with a minimum of six beds and a 24-hour ED. The sample includes separate strata for very large, large, medium, and small hospitals, defined by the number of annual ED visits per hospital, and children's hospitals. The scope of reporting goes beyond routine reporting of injuries associated with consumer-related products in CPSC's jurisdiction to include all injuries and poisonings. The data can be used to (1) measure the magnitude and distribution of nonfatal injuries in the United States; (2) monitor unintentional and violence-related nonfatal injuries over time; (3) identify emerging injury problems; (4) identify specific cases for follow-up investigations of particular injury-related problems; and (5) set national priorities. A fundamental principle of this expansion effort is that preliminary surveillance data will be made available in a timely manner to a number of different federal agencies with unique and overlapping public health responsibilities and concerns. Also, annually, the final edited data will be released as public use data files for use by other public health professionals and researchers. NEISS-AIP data on nonfatal injuries were collected from January through December each year except the year 2000 when data were collected from July through December (ICPSR 3582).

NEISS AIP is providing data on approximately over 500,000 cases annually. Data obtained on each case include age, race/ethnicity, gender, principal diagnosis, primary body part affected, consumer products involved, disposition at ED discharge (i.e., hospitalized, transferred, treated and released, observation, died), locale where the injury occurred, work-relatedness, and a narrative description of the injury circumstances. Also, major categories of external cause of injury (e.g., motor vehicle, falls, cut/pierce, poisoning, fire/burn) and of intent of injury (e.g., unintentional, assault, intentional self-harm, legal intervention) are being coded for each case in a manner consistent with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding rules and guidelines. NEISS has been managed and operated by the United States Consumer Product Safety Commission since 1972 and is used by the Commission for identifying and monitoring consumer product-related injuries and for assessing risk to all United States residents. These product-related injury data are used for educating consumers about hazardous products and for identifying injury-related cases used in detailed studies of specific products and associated hazard patterns. These studies set the stage for developing both voluntary and mandatory safety standards.

Since the early 1980s, CPSC has assisted other federal agencies by using NEISS to collect injury- related data of special interest to them. In 1990, an interagency agreement was established between NCIPC and CPSC to (1) collect NEISS data on nonfatal firearm-related injuries for the CDC Firearm Injury Surveillance Study; (2) publish NEISS data on a variety of injury-related topics, such as in-line skating, firearms, BB and pellet guns, bicycles, boat propellers, personal water craft, and playground injuries; and (3) to address common concerns. CPSC also uses NEISS to collect data on work-related injuries for the National Institute of Occupational Safety and Health (NIOSH), CDC. In 1997, the interagency agreement was modified to conduct the three-month NEISS All Injury Pilot Study at 21 NEISS hospitals (see Quinlan KP, Thompson MP, Annest JL, et al. Expanding the National Electronic Injury Surveillance System to Monitor All Nonfatal Injuries Treated in US Hospital Emergency Departments. Annals Emerg. Med. 1999;34:637-643.) This study demonstrated the feasibility of expanding NEISS to collect data on all injuries. National estimates based on this study indicated product-related injuries that fall into CPSC's jurisdiction accounted for approximately 50 percent of injuries treated in U.S. hospital EDs. The study also indicated that NEISS is a cost-effective system for capturing data on all injuries treated in U.S. hospital EDs. The NEISS-AIP provides an excellent data source for monitoring national estimates of nonfatal injuries over time. Analysis and dissemination of these surveillance data through the ICPSR, and Internet publications will help support NCIPC's mission of reducing all types and causes of injuries in the United States, as well as assist other federal agencies with responsibilities for injury prevention and control.

Beginning in July 2000, the National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention (CDC) in collaboration with the United States Consumer Product Safety Commission (CPSC) expanded the National Electronic Injury Surveillance System (NEISS) to collect data on all types and causes of injuries treated in a representative sample of United States hospitals with emergency departments (EDs). This system is called the NEISS-All Injury Program (NEISS-AIP).

The NEISS-AIP is designed to provide national incidence estimates of all types and external causes of nonfatal injuries and poisonings treated in U.S. hospital EDs. Data on injury-related visits are being obtained from a national sample of U.S. NEISS hospitals, which were selected as a stratified probability sample of hospitals in the United States and its territories with a minimum of six beds and a 24-hour ED. The sample includes separate strata for very large, large, medium, and small hospitals, defined by the number of annual ED visits per hospital, and children's hospitals. The scope of reporting goes beyond routine reporting of injuries associated with consumer-related products in CPSC's jurisdiction to include all injuries and poisonings. The data can be used to (1) measure the magnitude and distribution of nonfatal injuries in the United States; (2) monitor unintentional and violence-related nonfatal injuries over time; (3) identify emerging injury problems; (4) identify specific cases for follow-up investigations of particular injury-related problems; and (5) set national priorities. A fundamental principle of this expansion effort is that preliminary surveillance data will be made available in a timely manner to a number of different federal agencies with unique and overlapping public health responsibilities and concerns. Also, annually, the final edited data will be released as public use data files for use by other public health professionals and researchers. NEISS-AIP data on nonfatal injuries were collected from January through December each year except the year 2000 when data were collected from July through December (ICPSR 3582).

NEISS AIP is providing data on approximately over 500,000 cases annually. Data obtained on each case include age, race/ethnicity, gender, principal diagnosis, primary body part affected, consumer products involved, disposition at ED discharge (i.e., hospitalized, transferred, treated and released, observation, died), locale where the injury occurred, work-relatedness, and a narrative description of the injury circumstances. Also, major categories of external cause of injury (e.g., motor vehicle, falls, cut/pierce, poisoning, fire/burn) and of intent of injury (e.g., unintentional, assault, intentional self-harm, legal intervention) are being coded for each case in a manner consistent with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding rules and guidelines. NEISS has been managed and operated by the United States Consumer Product Safety Commission since 1972 and is used by the Commission for identifying and monitoring consumer product-related injuries and for assessing risk to all United States residents. These product-related injury data are used for educating consumers about hazardous products and for identifying injury-related cases used in detailed studies of specific products and associated hazard patterns. These studies set the stage for developing both voluntary and mandatory safety standards.

Since the early 1980s, CPSC has assisted other federal agencies by using NEISS to collect injury- related data of special interest to them. In 1990, an interagency agreement was established between NCIPC and CPSC to (1) collect NEISS data on nonfatal firearm-related injuries for the CDC Firearm Injury Surveillance Study; (2) publish NEISS data on a variety of injury-related topics, such as in-line skating, firearms, BB and pellet guns, bicycles, boat propellers, personal water craft, and playground injuries; and (3) to address common concerns. CPSC also uses NEISS to collect data on work-related injuries for the National Institute of Occupational Safety and Health (NIOSH), CDC. In 1997, the interagency agreement was modified to conduct the three-month NEISS All Injury Pilot Study at 21 NEISS hospitals (see Quinlan KP, Thompson MP, Annest JL, et al. Expanding the National Electronic Injury Surveillance System to Monitor All Nonfatal Injuries Treated in US Hospital Emergency Departments. Annals Emerg. Med. 1999;34:637-643.) This study demonstrated the feasibility of expanding NEISS to collect data on all injuries. National estimates based on this study indicated product-related injuries that fall into CPSC's jurisdiction accounted for approximately 50 percent of injuries treated in U.S. hospital EDs. The study also indicated that NEISS is a cost-effective system for capturing data on all injuries treated in U.S. hospital EDs. The NEISS-AIP provides an excellent data source for monitoring national estimates of nonfatal injuries over time. Analysis and dissemination of these surveillance data through the ICPSR, and Internet publications will help support NCIPC's mission of reducing all types and causes of injuries in the United States, as well as assist other federal agencies with responsibilities for injury prevention and control.

Beginning in July 2000, the National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention (CDC) in collaboration with the United States Consumer Product Safety Commission (CPSC) expanded the National Electronic Injury Surveillance System (NEISS) to collect data on all types and causes of injuries treated in a representative sample of United States hospitals with emergency departments (EDs). This system is called the NEISS-All Injury Program (NEISS-AIP).

The NEISS-AIP is designed to provide national incidence estimates of all types and external causes of nonfatal injuries and poisonings treated in U.S. hospital EDs. Data on injury-related visits are being obtained from a national sample of U.S. NEISS hospitals, which were selected as a stratified probability sample of hospitals in the United States and its territories with a minimum of six beds and a 24-hour ED. The sample includes separate strata for very large, large, medium, and small hospitals, defined by the number of annual ED visits per hospital, and children's hospitals. The scope of reporting goes beyond routine reporting of injuries associated with consumer-related products in CPSC's jurisdiction to include all injuries and poisonings. The data can be used to (1) measure the magnitude and distribution of nonfatal injuries in the United States; (2) monitor unintentional and violence-related nonfatal injuries over time; (3) identify emerging injury problems; (4) identify specific cases for follow-up investigations of particular injury-related problems; and (5) set national priorities. A fundamental principle of this expansion effort is that preliminary surveillance data will be made available in a timely manner to a number of different federal agencies with unique and overlapping public health responsibilities and concerns. Also, annually, the final edited data will be released as public use data files for use by other public health professionals and researchers. NEISS-AIP data on nonfatal injuries were collected from January through December each year except the year 2000 when data were collected from July through December (ICPSR 3582).

NEISS AIP is providing data on approximately over 500,000 cases annually. Data obtained on each case include age, race/ethnicity, gender, principal diagnosis, primary body part affected, consumer products involved, disposition at ED discharge (i.e., hospitalized, transferred, treated and released, observation, died), locale where the injury occurred, work-relatedness, and a narrative description of the injury circumstances. Also, major categories of external cause of injury (e.g., motor vehicle, falls, cut/pierce, poisoning, fire/burn) and of intent of injury (e.g., unintentional, assault, intentional self-harm, legal intervention) are being coded for each case in a manner consistent with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding rules and guidelines. NEISS has been managed and operated by the United States Consumer Product Safety Commission since 1972 and is used by the Commission for identifying and monitoring consumer product-related injuries and for assessing risk to all United States residents. These product-related injury data are used for educating consumers about hazardous products and for identifying injury-related cases used in detailed studies of specific products and associated hazard patterns. These studies set the stage for developing both voluntary and mandatory safety standards.

Since the early 1980s, CPSC has assisted other federal agencies by using NEISS to collect injury- related data of special interest to them. In 1990, an interagency agreement was established between NCIPC and CPSC to (1) collect NEISS data on nonfatal firearm-related injuries for the CDC Firearm Injury Surveillance Study; (2) publish NEISS data on a variety of injury-related topics, such as in-line skating, firearms, BB and pellet guns, bicycles, boat propellers, personal water craft, and playground injuries; and (3) to address common concerns. CPSC also uses NEISS to collect data on work-related injuries for the National Institute of Occupational Safety and Health (NIOSH), CDC. In 1997, the interagency agreement was modified to conduct the three-month NEISS All Injury Pilot Study at 21 NEISS hospitals (see Quinlan KP, Thompson MP, Annest JL, et al. Expanding the National Electronic Injury Surveillance System to Monitor All Nonfatal Injuries Treated in US Hospital Emergency Departments. Annals Emerg. Med. 1999;34:637-643.) This study demonstrated the feasibility of expanding NEISS to collect data on all injuries. National estimates based on this study indicated product-related injuries that fall into CPSC's jurisdiction accounted for approximately 50 percent of injuries treated in U.S. hospital EDs. The study also indicated that NEISS is a cost-effective system for capturing data on all injuries treated in U.S. hospital EDs. The NEISS-AIP provides an excellent data source for monitoring national estimates of nonfatal injuries over time. Analysis and dissemination of these surveillance data through the ICPSR, and Internet publications will help support NCIPC's mission of reducing all types and causes of injuries in the United States, as well as assist other federal agencies with responsibilities for injury prevention and control.

This study was conducted to address elder abuse within emergency departments in the United States. The aim of this study was to develop a screening protocol or more specifically, an emergency department based tool to discover this specific abuse and try to eliminate it.

This emergency department senior aid tool was created in two phases: the development phase and the validation phase. The purpose of the development phase was to test the reliability of this tool in detecting elder abuse in ages 65 and older individuals. On the other hand, the validation phase was to test the tool at three different locations: UNC Medical Center in Chapel Hill, North Carolina, Cooper Hospital in Camden, New Jersey, and University of Florida Health in Jacksonville, Florida.

Beginning in July 2000, the National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention (CDC) in collaboration with the United States Consumer Product Safety Commission (CPSC) expanded the National Electronic Injury Surveillance System (NEISS) to collect data on all types and causes of injuries treated in a representative sample of United States hospitals with emergency departments (EDs). This system is called the NEISS-All Injury Program (NEISS-AIP).

The NEISS-AIP is designed to provide national incidence estimates of all types and external causes of nonfatal injuries and poisonings treated in U.S. hospital EDs. Data on injury-related visits are being obtained from a national sample of U.S. NEISS hospitals, which were selected as a stratified probability sample of hospitals in the United States and its territories with a minimum of six beds and a 24-hour ED. The sample includes separate strata for very large, large, medium, and small hospitals, defined by the number of annual ED visits per hospital, and children's hospitals. The scope of reporting goes beyond routine reporting of injuries associated with consumer-related products in CPSC's jurisdiction to include all injuries and poisonings. The data can be used to (1) measure the magnitude and distribution of nonfatal injuries in the United States; (2) monitor unintentional and violence-related nonfatal injuries over time; (3) identify emerging injury problems; (4) identify specific cases for follow-up investigations of particular injury-related problems; and (5) set national priorities. A fundamental principle of this expansion effort is that preliminary surveillance data will be made available in a timely manner to a number of different federal agencies with unique and overlapping public health responsibilities and concerns. Also, annually, the final edited data will be released as public use data files for use by other public health professionals and researchers. NEISS-AIP data on nonfatal injuries were collected from January through December each year except the year 2000 when data were collected from July through December (ICPSR 3582).

NEISS AIP is providing data on approximately over 500,000 cases annually. Data obtained on each case include age, race/ethnicity, gender, principal diagnosis, primary body part affected, consumer products involved, disposition at ED discharge (i.e., hospitalized, transferred, treated and released, observation, died), locale where the injury occurred, work-relatedness, and a narrative description of the injury circumstances. Also, major categories of external cause of injury (e.g., motor vehicle, falls, cut/pierce, poisoning, fire/burn) and of intent of injury (e.g., unintentional, assault, intentional self-harm, legal intervention) are being coded for each case in a manner consistent with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding rules and guidelines. NEISS has been managed and operated by the United States Consumer Product Safety Commission since 1972 and is used by the Commission for identifying and monitoring consumer product-related injuries and for assessing risk to all United States residents. These product-related injury data are used for educating consumers about hazardous products and for identifying injury-related cases used in detailed studies of specific products and associated hazard patterns. These studies set the stage for developing both voluntary and mandatory safety standards.

Since the early 1980s, CPSC has assisted other federal agencies by using NEISS to collect injury- related data of special interest to them. In 1990, an interagency agreement was established between NCIPC and CPSC to (1) collect NEISS data on nonfatal firearm-related injuries for the CDC Firearm Injury Surveillance Study; (2) publish NEISS data on a variety of injury-related topics, such as in-line skating, firearms, BB and pellet guns, bicycles, boat propellers, personal water craft, and playground injuries; and (3) to address common concerns. CPSC also uses NEISS to collect data on work-related injuries for the National Institute of Occupational Safety and Health (NIOSH), CDC. In 1997, the interagency agreement was modified to conduct the three-month NEISS All Injury Pilot Study at 21 NEISS hospitals (see Quinlan KP, Thompson MP, Annest JL, et al. Expanding the National Electronic Injury Surveillance System to Monitor All Nonfatal Injuries Treated in US Hospital Emergency Departments. Annals Emerg. Med. 1999;34:637-643.) This study demonstrated the feasibility of expanding NEISS to collect data on all injuries. National estimates based on this study indicated product-related injuries that fall into CPSC's jurisdiction accounted for approximately 50 percent of injuries treated in U.S. hospital EDs. The study also indicated that NEISS is a cost-effective system for capturing data on all injuries treated in U.S. hospital EDs. The NEISS-AIP provides an excellent data source for monitoring national estimates of nonfatal injuries over time. Analysis and dissemination of these surveillance data through the ICPSR, and Internet publications will help support NCIPC's mission of reducing all types and causes of injuries in the United States, as well as assist other federal agencies with responsibilities for injury prevention and control.

Beginning in July 2000, the National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention (CDC) in collaboration with the United States Consumer Product Safety Commission (CPSC) expanded the National Electronic Injury Surveillance System (NEISS) to collect data on all types and causes of injuries treated in a representative sample of United States hospitals with emergency departments (EDs). This system is called the NEISS-All Injury Program (NEISS-AIP).

The NEISS-AIP is designed to provide national incidence estimates of all types and external causes of nonfatal injuries and poisonings treated in U.S. hospital EDs. Data on injury-related visits are being obtained from a national sample of U.S. NEISS hospitals, which were selected as a stratified probability sample of hospitals in the United States and its territories with a minimum of six beds and a 24-hour ED. The sample includes separate strata for very large, large, medium, and small hospitals, defined by the number of annual ED visits per hospital, and children's hospitals. The scope of reporting goes beyond routine reporting of injuries associated with consumer-related products in CPSC's jurisdiction to include all injuries and poisonings. The data can be used to (1) measure the magnitude and distribution of nonfatal injuries in the United States; (2) monitor unintentional and violence-related nonfatal injuries over time; (3) identify emerging injury problems; (4) identify specific cases for follow-up investigations of particular injury-related problems; and (5) set national priorities. A fundamental principle of this expansion effort is that preliminary surveillance data will be made available in a timely manner to a number of different federal agencies with unique and overlapping public health responsibilities and concerns. Also, annually, the final edited data will be released as public use data files for use by other public health professionals and researchers. NEISS-AIP data on nonfatal injuries were collected from January through December each year except the year 2000 when data were collected from July through December (ICPSR 3582).

NEISS AIP is providing data on approximately over 500,000 cases annually. Data obtained on each case include age, race/ethnicity, gender, principal diagnosis, primary body part affected, consumer products involved, disposition at ED discharge (i.e., hospitalized, transferred, treated and released, observation, died), locale where the injury occurred, work-relatedness, and a narrative description of the injury circumstances. Also, major categories of external cause of injury (e.g., motor vehicle, falls, cut/pierce, poisoning, fire/burn) and of intent of injury (e.g., unintentional, assault, intentional self-harm, legal intervention) are being coded for each case in a manner consistent with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding rules and guidelines. NEISS has been managed and operated by the United States Consumer Product Safety Commission since 1972 and is used by the Commission for identifying and monitoring consumer product-related injuries and for assessing risk to all United States residents. These product-related injury data are used for educating consumers about hazardous products and for identifying injury-related cases used in detailed studies of specific products and associated hazard patterns. These studies set the stage for developing both voluntary and mandatory safety standards.

Since the early 1980s, CPSC has assisted other federal agencies by using NEISS to collect injury- related data of special interest to them. In 1990, an interagency agreement was established between NCIPC and CPSC to (1) collect NEISS data on nonfatal firearm-related injuries for the CDC Firearm Injury Surveillance Study; (2) publish NEISS data on a variety of injury-related topics, such as in-line skating, firearms, BB and pellet guns, bicycles, boat propellers, personal water craft, and playground injuries; and (3) to address common concerns. CPSC also uses NEISS to collect data on work-related injuries for the National Institute of Occupational Safety and Health (NIOSH), CDC. In 1997, the interagency agreement was modified to conduct the three-month NEISS All Injury Pilot Study at 21 NEISS hospitals (see Quinlan KP, Thompson MP, Annest JL, et al. Expanding the National Electronic Injury Surveillance System to Monitor All Nonfatal Injuries Treated in US Hospital Emergency Departments. Annals Emerg. Med. 1999;34:637-643.) This study demonstrated the feasibility of expanding NEISS to collect data on all injuries. National estimates based on this study indicated product-related injuries that fall into CPSC's jurisdiction accounted for approximately 50 percent of injuries treated in U.S. hospital EDs. The study also indicated that NEISS is a cost-effective system for capturing data on all injuries treated in U.S. hospital EDs. The NEISS-AIP provides an excellent data source for monitoring national estimates of nonfatal injuries over time. Analysis and dissemination of these surveillance data through the ICPSR, and Internet publications will help support NCIPC's mission of reducing all types and causes of injuries in the United States, as well as assist other federal agencies with responsibilities for injury prevention and control.

Beginning in July 2000, the National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention (CDC) in collaboration with the United States Consumer Product Safety Commission (CPSC) expanded the National Electronic Injury Surveillance System (NEISS) to collect data on all types and causes of injuries treated in a representative sample of United States hospitals with emergency departments (EDs). This system is called the NEISS-All Injury Program (NEISS-AIP).

The NEISS-AIP is designed to provide national incidence estimates of all types and external causes of nonfatal injuries and poisonings treated in U.S. hospital EDs. Data on injury-related visits are being obtained from a national sample of U.S. NEISS hospitals, which were selected as a stratified probability sample of hospitals in the United States and its territories with a minimum of six beds and a 24-hour ED. The sample includes separate strata for very large, large, medium, and small hospitals, defined by the number of annual ED visits per hospital, and children's hospitals. The scope of reporting goes beyond routine reporting of injuries associated with consumer-related products in CPSC's jurisdiction to include all injuries and poisonings. The data can be used to (1) measure the magnitude and distribution of nonfatal injuries in the United States; (2) monitor unintentional and violence-related nonfatal injuries over time; (3) identify emerging injury problems; (4) identify specific cases for follow-up investigations of particular injury-related problems; and (5) set national priorities. A fundamental principle of this expansion effort is that preliminary surveillance data will be made available in a timely manner to a number of different federal agencies with unique and overlapping public health responsibilities and concerns. Also, annually, the final edited data will be released as public use data files for use by other public health professionals and researchers. NEISS-AIP data on nonfatal injuries were collected from January through December each year except the year 2000 when data were collected from July through December (ICPSR 3582).

NEISS AIP is providing data on approximately over 500,000 cases annually. Data obtained on each case include age, race/ethnicity, gender, principal diagnosis, primary body part affected, consumer products involved, disposition at ED discharge (i.e., hospitalized, transferred, treated and released, observation, died), locale where the injury occurred, work-relatedness, and a narrative description of the injury circumstances. Also, major categories of external cause of injury (e.g., motor vehicle, falls, cut/pierce, poisoning, fire/burn) and of intent of injury (e.g., unintentional, assault, intentional self-harm, legal intervention) are being coded for each case in a manner consistent with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding rules and guidelines. NEISS has been managed and operated by the United States Consumer Product Safety Commission since 1972 and is used by the Commission for identifying and monitoring consumer product-related injuries and for assessing risk to all United States residents. These product-related injury data are used for educating consumers about hazardous products and for identifying injury-related cases used in detailed studies of specific products and associated hazard patterns. These studies set the stage for developing both voluntary and mandatory safety standards.

Since the early 1980s, CPSC has assisted other federal agencies by using NEISS to collect injury- related data of special interest to them. In 1990, an interagency agreement was established between NCIPC and CPSC to (1) collect NEISS data on nonfatal firearm-related injuries for the CDC Firearm Injury Surveillance Study; (2) publish NEISS data on a variety of injury-related topics, such as in-line skating, firearms, BB and pellet guns, bicycles, boat propellers, personal water craft, and playground injuries; and (3) to address common concerns. CPSC also uses NEISS to collect data on work-related injuries for the National Institute of Occupational Safety and Health (NIOSH), CDC. In 1997, the interagency agreement was modified to conduct the three-month NEISS All Injury Pilot Study at 21 NEISS hospitals (see Quinlan KP, Thompson MP, Annest JL, et al. Expanding the National Electronic Injury Surveillance System to Monitor All Nonfatal Injuries Treated in US Hospital Emergency Departments. Annals Emerg. Med. 1999;34:637-643.) This study demonstrated the feasibility of expanding NEISS to collect data on all injuries. National estimates based on this study indicated product-related injuries that fall into CPSC's jurisdiction accounted for approximately 50 percent of injuries treated in U.S. hospital EDs. The study also indicated that NEISS is a cost-effective system for capturing data on all injuries treated in U.S. hospital EDs. The NEISS-AIP provides an excellent data source for monitoring national estimates of nonfatal injuries over time. Analysis and dissemination of these surveillance data through the ICPSR, and Internet publications will help support NCIPC's mission of reducing all types and causes of injuries in the United States, as well as assist other federal agencies with responsibilities for injury prevention and control.

These data are part of NACJD's Fast Track Release and are distributed as they were received from the data depositor. The files have been zipped by NACJD for release, but not checked or processed except for the removal of direct identifiers. Users should refer to the accompanying readme file for a brief description of the files available with this collection and consult the investigator(s) if further information is needed.

The study investigated the feasibility of implementing the Cardiff Model. The Cardiff Model is a unique violence surveillance system and intervention that involves data sharing and violence prevention planning between law enforcement and the medical field. Anonymized data on assaults from emergency and police departments (EDs; PDs) are combined to detail assault incidents and "hotspots." Data are discussed by a multidisciplinary consortium, which develops and implements a data-informed violence prevention action plan that includes behavioral, environmental, and policy changes to impact violence. Model actions led to decreases in injurious assaults and this model is now statutory in the United Kingdom.

The Cardiff Model has never been translated to the U.S. and would require an investigation within our health care system and in different geographical and population contexts. This study investigated the feasibility of essential Cardiff Model Components in order to refine study procedures and situate this community to request further funds for full model implementation.

As part of this study, researchers collected a number of feasibility measures from ED and study staff to evaluate the feasibility of translating included model components. Geospatial and statistical analyses investigated the added benefit of the combined ED, PD and Emergency Medical Services (EMS) data.

The study contains 1 SPSS data files (CHW Data_1.1.15 to 7.31.16.sav (n=748; 14 variables)), 1 STATA data file (nurse survey data.dta (n=43; 26 variables)), a text document (Nurse Survey_Qualitative data.txt), and 1 excel file (CHW Incidents_Block level data only.xlsx).

The Tailored Teen Alcohol and Violence Prevention in the Emergency Room survey screened 3,338 adolescents in an urban emergency department (ED) over a 30-month collection period. Eligible adolescents who self-reported alcohol misuse and violence were asked to participate in a longitudinal study to assess the efficacy of various brief interventions (BIs) at reducing peer violence, victimization, and substance abuse.

Patients aged 14 to 18 years who presented for medical illness or injury were eligible for screening (see Sampling exclusions). Recruitment occurred between 12pm and 11pm, 7 days a week (September 2006-September 2009), excluding major holidays. Adolescent patients identified from electronic logs were approached by research assistants in waiting rooms or treatment spaces. Following obtainment of written consent (and assent and parent/guardian consent if under 18 years of age), participants self-administered a 15-minute computerized survey with audio. After completing the survey, participants reporting both past-year aggression (peer, dating, weapon carriage/use) and alcohol consumption were eligible to enroll in the longitudinal study. Participants reporting only 1 behavior (aggression or alcohol use) were not eligible.

Following obtainment of written consent (and assent and parent/guardian consent if under 18 years of age) for the longitudinal study, participants self-administered a computerized baseline assessment. Participants were informed that they would be randomly assigned to 1 of 3 groups: computer session, counselor session, or brochure. Participants were blinded to condition assignment until after the baseline assessment. After the baseline, participants were randomized and received the therapist brief intervention, computer brief intervention, or control brochure during the ED visit.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

Objective

A significant number of patients with unexplained chest pain (UCP) have panic disorder (PD), and most individuals with panic disorder (PD) report poor sleep, including insomnia and nocturnal panic attacks (NPA). The objective of the study was to examine the impact of treatment for PD on sleep problems and to assess the influence of pre-treatment insomnia on post-treatment persistence of PD diagnosis and pain severity.

Methods

Secondary analyses were conducted on sleep data collected from 42 PD patients consulting emergency departments (ED) for UCP. In this quasi-experimental design, cohorts of participants were randomly assigned to one of four conditions: (1) seven sessions of cognitive-behavior therapy (CBT) for PD, (2) a one-session panic management intervention, (3) pharmacotherapy, or (4) usual care. Data from clinical interviews performed by trained assistants and from self-report questionnaires were collected before and after treatment. Results after treatment, 35 percent of participants still met the diagnostic criteria for insomnia, and 20 percent of the sample still reported NPA. The presence of insomnia was a predictor of post-treatment pain severity (B = 1.336, SE B = .483, p = .009), regardless of the severity of pre-treatment anxiety and depressive symptoms or of assignation to an active PD treatment.

Conclusions

Treatment for PD had a small effect on sleep, and residual sleep difficulties persisted after treatment. More importantly, the presence of insomnia was a significant predictor of persistent pain after treatment. The results highlight the importance of careful assessment of sleep before and during treatment for PD in UCP patients.

In 2008, a group of uninsured low-income adults in Oregon was selected by lottery to be given the chance to apply for Medicaid. This lottery provides an opportunity to gauge the effects of expanding access to public health insurance on the health care use, financial strain, and health of low-income adults using a randomized controlled design. The Oregon Health Insurance Experiment follows and compares those selected in the lottery (treatment group) with those not selected (control group). The data collected and provided here include data from in-person interviews, three mail surveys, emergency department records, and administrative records on Medicaid enrollment, the initial lottery sign-up list, welfare benefits, and mortality.

This data collection has seven data files:

Dataset 1 contains administrative data on the lottery from the state of Oregon. These data include demographic characteristics that were recorded when individuals signed up for the lottery, date of lottery draw, and information on who was selected for the lottery, applied for the lotteried Medicaid plan if selected, and whose application for the lotteried plan was approved. Also included are Oregon mortality data for 2008 and 2009.

Dataset 2 contains information from the state of Oregon on the individuals' participation in Medicaid, Supplemental Nutrition Assistance Program (SNAP), and Temporary Assistance to Needy Families (TANF).

Datasets 3-5 contain the data from the initial, six month, and 12 month mail surveys, respectively. Topics covered by the surveys include demographic characteristics; health insurance, access to health care and health care utilization; health care needs, experiences, and costs; overall health status and changes in health; and depression and medical conditions and use of medications to treat them.

Dataset 6 contains an analysis subset of the variables from the in-person interviews. Topics covered by the survey questionnaire include overall health, health insurance coverage, health care access, health care utilization, conditions and treatments, health behaviors, medical and dental costs, and demographic characteristics. The interviewers also obtained blood pressure and anthropometric measurements and collected dried blood spots to measure levels of cholesterol, glycated hemoglobin and C-reactive protein.

Dataset 7 contains an analysis subset of the variables the study obtained for all emergency department (ED) visits to twelve hospitals in the Portland area during 2007-2009. These variables capture total hospital costs, ED costs, and the number of ED visits categorized by time of the visit (daytime weekday or nighttime and weekends), necessity of the visit (emergent, ED care needed, non-preventable; emergent, ED care needed, preventable; emergent, primary care treatable), ambulatory case sensitive status, whether or not the patient was hospitalized, and the reason for the visit (e.g., injury, abdominal pain, chest pain, headache, and mental disorders).

The collection also includes a ZIP archive (Dataset 8) with Stata programs that replicate analyses reported in three articles by the principal investigators and others:

Finkelstein, Amy et al "The Oregon Health Insurance Experiment: Evidence from the First Year". The Quarterly Journal of Economics. August 2012. Vol 127(3).

Baicker, Katherine et al "The Oregon Experiment - Effects of Medicaid on Clinical Outcomes". New England Journal of Medicine. 2 May 2013. Vol 368(18).

Taubman, Sarah et al "Medicaid Increases Emergency Department Use: Evidence from Oregon's Health Insurance Experiment". Science. 2 Jan 2014.